Legal Representation
Attorney
Aaron D. Hendelman
USPTO Deadlines
Next Deadline
1544 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-10-24)
Due Date
October 24, 2029
Grace Period Ends
April 24, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
35 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 24, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Oct 24, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Sep 22, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Sep 21, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Aug 20, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Aug 20, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Aug 10, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Aug 10, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Aug 8, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 4, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Aug 4, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Aug 4, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 15, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 13, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 13, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 13, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 23, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 28, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 28, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 8, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 19, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 11, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 11, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 11, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 22, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 22, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 22, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 21, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 18, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Feb 18, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Feb 18, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Feb 18, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Feb 18, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Nov 8, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 26, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, oncological, hepatological, ophthalmic, respiratory, central and/or peripheral neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
First Use Anywhere:
Aug 2, 2021
First Use in Commerce:
Aug 2, 2021
Classification
International Classes
005